Oct 12 (Reuters) - Human Stem Cells Institute ISKJ.MM :
* Says it has licensed the exclusive U.S. and Canadian rights for Neovasculgen to ArtGen, Inc., a privately held biotechnology company located in Rockville, MD
* Neovasculgen is a first-in-class gene therapy drug that was approved in 2011 for human use in Russia for treatment of atherosclerotic Peripheral Arterial Disease, including Critical Limb Ischemia
* Says it will receive milestone payments, royalties and future equity participation rights in ArtGen
Source text: company coverage: ISKJ.MM
(Gdynia Newsroom)